Image | Paixin Creative

• $370 Million! Olympus Completes Acquisition

• Karl Storz Acquires ISL

KARL STORZ VentureONE General Manager Stephan Abele stated, "ISL's expertise in artificial intelligence applications will greatly advance the development of our robotic products. Therefore, we are very much looking forward to our collaboration and growing together in this field."

• GE Healthcare Announces Acquisition of MIM Software

MIM Software was founded in 2003, with its headquarters in Cleveland, Ohio, and offices in Beijing, Chengdu in China, and Brussels, Belgium.MIM Software, Inc. provides medical image analysis for imaging centers, hospitals, specialty clinics, research institutions, and pharmaceutical companies worldwide.Artificial Intelligence AISolutions, with product applications in multiple fields such as radiation oncology, nuclear medicine molecular imaging, neurology, and cardiovascular disease diagnosis and treatment.

GE Healthcare stated,Hope to integrate MIM Software's innovative solutions into its advanced visualization products to promote the application of digital technologies, including AI-based lesion segmentation and contouring, dose analysis in radiotherapy, etc., at all stages of disease diagnosis and treatment—especially in the rapidly growing fields of radiology imaging, nuclear medicine molecular imaging, and radiation oncology.

• $3.7 Billion! Boston Scientific Acquires Axonics

Recently,Boston Scientific Corporation Announces Definitive Agreement to Acquire Axonics, Inc.Axonics, Inc. is a publicly listed medical technology company primarily dedicated to developing and selling innovative products for the treatment of bladder and bowel dysfunction. The acquisition price was $71 per share in an all-cash transaction, with an equity value of approximately $3.7 billion.The industry value is approximately US$3.4 billion.

• Mindray Acquires Control of APT Medical

• Smith & Nephew Acquires Orthopedic Implant Device Company

Recently,Smith & Nephew announces completion of acquisition of CartiHeal.As previously disclosed, Smith & Nephew has paid $180 million upon the completion of the acquisition and may pay up to an additional $150 million based on financial performance in the future.

CartiHeal's Agili-C is a disruptive innovative technology for knee cartilage regeneration. It was announced that the acquisition of CartiHeal has been completed. CartiHeal's Agili-C is a disruptive innovative technology for knee cartilage regeneration.

Agili-C provides a ready-to-use, one-step solution for osteochondral (bone and cartilage) injury treatment. Its application scope is broader than existing treatments, covering patient groups including those with mild to moderate osteoarthritis, as well as approximately 700,000 patients in the U.S. who undergo cartilage repair treatment each year.

• Danaher Completes Acquisition of Abcam

December 6, 2023Danaher Completed the Transaction at $24 Per Share in CashAbcamThe acquisition.Public information shows that Abcam is a globally renowned antibody supplier, providing scientists with a variety of laboratory products, such as proteins and antibodies used for drug discovery and diagnostics.

In its latest financial report, President and CEO Rainer M.Blair said:The recent completion of the acquisition of Abcam has enhanced our product portfolio and expanded our capabilities in the highly attractive proteomics market.

Previously, Rainer M. Blair pointed out in a teleconference that,Abcam will become an independently operated company under Danaher Life Sciences, further advancing Danaher's strategy to help map complex disease pathways and accelerate drug development.

• Carl Zeiss Meditec Acquires 100% Stake in DORC for €760 Million

On December 15, 2023, Carl Zeiss Meditec announced,Will acquire 100% of the equity of Dutch Ophthalmic Research Center (DORC) from French investment company Eurazeo for a total price of 985 million euros (approximately 1.07 billion US dollars; 7.6 billion RMB).

It is reported that DORC is a manufacturer specializing in the research, development, and provision of highly innovative ophthalmic products and solutions. The company is renowned for its advanced technology and innovative products, particularly achieving significant success in the field of vitreoretinal surgery. Its product portfolio includes ophthalmic surgical equipment, disposable supplies, and liquid products, which are widely used in the treatment of various ophthalmic diseases, including retinal disorders, cataracts, glaucoma, and refractive errors.

Carl Zeiss Meditec plans to integrate DORC's advanced technologies and product portfolio through this acquisition, enhancing its market share in the vitreoretinal surgery field while strengthening its position as the "fastest-growing ophthalmic medical device manufacturer" globally. The transaction is expected to be completed in the first half of 2024.

• Allgens Medical Acquires German Medical Device Company

On December 22, 2023, Allgens Medical's official WeChat public account announced,Allgens Medical Technology CO.,LTD. plans to acquire HumanTech Dental GmbH ("HT Dental") for 3.246 million euros. After the acquisition, Allgens Medical will hold 100% of HT Dental's shares.

Allgens Medical was founded in 2004 and is a national high-tech enterprise dedicated to the research, development, production, and sales of tissue regeneration and repair implantable medical devices.

The acquisition of 100% equity in Germany's HT Dental will strongly drive the further development of Allgens Medical's related business in the dental implantology field, enhance synergy between both parties, fully leverage the advantages of cross-border technology and marketing, provide customers with a more comprehensive product portfolio in the dental field, and accelerate the realization of a one-stop solution from product development to large-scale production.

Editor: Qin Jiu

WeChat ID: nrzx0321